Serotonin and CGRP in migraine

Milan Aggarwal, Veena Puri, Sanjeev Puri, Milan Aggarwal, Veena Puri, Sanjeev Puri

Abstract

Migraine is defined as recurrent attack of headache that are commonly unilateral and accompanied by gastrointestinal and visual disorders. Migraine is more prevalent in females than males with a ratio of 3:1. It is primarily a complex neurovascular disorder involving local vasodilation of intracranial, extracerebral blood vessels and simultaneous stimulation of surrounding trigeminal sensory nervous pain pathway that results in headache. The activation of 'trigeminovascular system' causes release of various vasodilators, especially calcitonin gene-related peptide (CGRP) that induces pain response. At the same time, decreased levels of neurotransmitter, serotonin have been observed in migraineurs. Serotonin receptors have been found on the trigeminal nerve and cranial vessels and their agonists especially triptans prove effective in migraine treatment. It has been found that triptans act on trigeminovascular system and bring the elevated serum levels of key molecules like calcitonin gene related peptide (CGRP) to normal. Currently CGRP receptor antagonists, olcegepant and telcagepant are under consideration for antimigraine therapeutics. It has been observed that varying levels of ovarian hormones especially estrogen influence serotonin neurotransmission system and CGRP levels making women more predisposed to migraine attacks. This review provides comprehensive information about the role of serotonin and CGRP in migraine, specifically the menstrual migraine.

Keywords: CGRP; Menstrual migraine; Migraine; Serotonin; Trigeminal ganglia.

Conflict of interest statement

Competing interests – None

Figures

Fig. 1:
Fig. 1:
Schematic pathway of the central processes of trigeminal ganglion neurons to the higher centers of brain.

References

    1. Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Diord. 2010;3(6):369–378.
    1. Robbins MS, Lipton RB. The epidemiology of primary headache disorders. Semin Neurol. 2010;30(2):107–109.
    1. Menon R. Women more prone to headaches: study. Deccan Herald N S. 2011 Apr 25th;
    1. Eriksen MK, Thomsen LL, Olesen J. New international classification of migraine with aura (ICHD-2) applied to 362 migraine patients. Er J Neurol. 2004;11:583–591.
    1. Tottene A, Conti R, Fabbro A et al. Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron. 2009;61(5):762–773.
    1. Stam AH, van den Maagdenberg AM, Haan J et al. Genetics of migraine: an update with special attention to genetic comorbidity. Curr Opin Neurol. 2008;21(3):288–293.
    1. Johnston D, Magee JC, Colbert CM, Cristie BR. Active properties of neuronal dendrites. Annu Rev Neurosci. 1996;19:165–186.
    1. Kakisaka Y, Wakusaka K, Haginoya K et al. Abdominal migraine associated with ecchymosis of legs and buttocks: does the symptom imply an unknown mechanism of migraine? Tohoku J Exp Med. 2010;221:49–51.
    1. Martin V, Wernke S, Mandell K et al. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45:1190–1201.
    1. Lambert GA. The lack of peripheral pathology in migraine headache. Headache Curr. 2010;50(5)
    1. Fields HL, Malick A, Burstein R. Dorsal horn projection targets of ON and OFF cells in the rostral ventromedial medulla. J Neurophysiol. 1995;74:1742–1759.
    1. Basbaum AI, Fields HL. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309–338.
    1. Levy D. Migraine pain and nociceptor activation- where do we stand? Headache Curr. 2010:909–916.
    1. Wolff HG. 2nd ed. New York: Oxford University Press; 1963. Headache and other head pain.
    1. Ninck B. Migraine and epilepsy. Eur Neurol. 1970;3
    1. Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett. 1999;266:173–176.
    1. Sicuteri F. Migraine: a central biochemical dysnociception. Headache. 1976;16:145–159.
    1. Sicuteri F. Headache as possible expression of deficiency of brain 5-hydroxytryptamine (central denervation supersensitivity). Headache. 1972;12:69–72.
    1. Schoonman GG, van der Grond J, Kortmann C et al. Migraine headache is not associated with cerebral or meningeal vasodilatation- a 3T magnetic resonance angiography study. Brain. 2008;131(8)
    1. Kruuse C, Thomsen LL, Birk S et al. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003;126(1)
    1. Rahmann A, Wienecke T, Hansen JM et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2007;28(3):226–236.
    1. Reuter U, Bolay H, Jansen-Olesen I et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain. 2001;124:2490–2502.
    1. Gargus JJ. Genetic calcium signaling abnormalities in the central nervous system: seizures, migraine and autism. Annals N Y Acad Sci. 2009:138–156.
    1. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 1993;5:159–177.
    1. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7
    1. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry. 1941;46:331–333.
    1. Van den Maagdenberg AM, Pietrobon D, Pizzorusso T et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004;41:701–710.
    1. Nozari A, Dilekoz E, Sukhotinsky I et al. Microemboli may link spreading depression migraine aura and patent foramen ovale (p NA). Ann Neurol. 2009 (In press)
    1. Noseda R, Kainz V, Jakubowski M et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci. 2010;13(2):239–245.
    1. Martin PR. Behavioral management of migraine headache triggers: learning to cope with triggers. Curr Pain Headache Rep. 2010;14:221–227.
    1. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27:394–402.
    1. Eikermann-Haerter K, Ayata C. Cortical spreading depression and migraine. Curr Neurol Neurosci Rep. 2010;10:167–173.
    1. Ravishankar K. Barriers to headache care in India and efforts to improve the situation. Lancet. 2004;3(9):564–567.
    1. Michael L, Oshinsky , Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006;46(Suppl 1)
    1. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010;24(7):539–548.
    1. Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994;14:320–323.
    1. Aurora S, Kulthia A, Barrodale P M. Mechanism of chronic migraine. Curr Pain Headache Rep. 2011;15:57–63.
    1. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine- new insights. Can J Neurol Sci. 1999;26(3):12–19.
    1. Moskowitz M A, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann Neurol. 2004;55(2):276–280.
    1. Berman NEJ, Puri V, Chandrala S et al. Serotonin in trigeminal ganglia of female rodents: relevance to menstrual migraine. Headache. 2006;46:1230–1234.
    1. Ferrari M D, Odink J, Tapparelli C et al. Serotonin metabolism in migraine. Neurol. 1989;39:1239–1242.
    1. Taylor B K, Basbaum A I. Neurochemical characterization of extracellular serotonin in the rostral ventromedial medulla and its modulation by noxious stimuli. J Neurochem. 1995;65(2):578–589.
    1. Comings DE. Serotonin: a key to migraine disorders? Nutrition Health Review, Health and Fitness Magazine. 1994
    1. Agranoff BW, Fisher SK, Albers RW . Siegel (Sixth, Lippincott Williams and Wilkins); 1999. Understanding the neuroanatomical organization of serotonergic cells in the brain provides insight into the functions of this neurotransmitter, in Basic Neurochemistry.
    1. Zhang X, Beaulieu JM, Sotnikova TD et al. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science. 2004;305
    1. Bianchi P, Kunduzova O, Masini E et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation. 2005;112(21):3297–3305.
    1. Moreno MJ, de Pablo ALL, Marco EJ. Tryptophan hydroxylase activity in rat brain base arteries related to innervation originating from the dorsal raphe nucleus. Stroke. 1994;25:1046–1049.
    1. Zhang X, Beaulieu JM, Gainetdinov RR et al. Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci. 2006;63(1):6–11.
    1. Stoyanova I I, Lazarov N E. Localization of nitric oxide synthase in rat trigeminal primary afferent neurons using NADPH-diaphorase histochemistry. J Mol Histol. 2005;36:187–193.
    1. Ramachandran R, Ploug K B, Schmidt A H, Olesen J, Jansen-Olesen I, Gupta S. Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats. Neurosci Lett. 2010 [Epub ahead of print]
    1. MacKenzie E T, Edvinsson L. (Amsterdam) 1980. Cerebral circulation and neurotransmitters, in Excerpta Medica; 163 pp.
    1. Meneses A. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Terapeutica Experimental Rev Neurosci. 1998;9(4):275–289.
    1. Hu W P, Guan B C, Ru L Q, Chen J G et al. Potentiation of 5-HT3 receptor function by the activation of coexistent 5-HT2 receptors in trigeminal ganglion neurons of rats. Neuropharmacol. 2004;47(6):833–840.
    1. Rebeck GW, Maynardti KI, Hyman BT et al. Selective 5-HT1Da serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA. 1994;91:3666–3669.
    1. Lin S L, Setya S, Johnson-Farley N N, Cowen D S. Differential coupling of 5-HT1 receptors to G proteins of the Gi family. British J Pharmacol. 2002;136:1072–1078.
    1. Apud JA, Grayson DR, De Erausquin E, Costa E. Pharmacological characterization of regulation of phosphoinositide metabolism by recombinant 5-HT2 receptors of the rat. Neuropharmacol. 1992;31:1–8.
    1. Brewerton TD, Murphy DL, Meuller EA et al. Induction of migraine-like headaches by the serotonin agonist, m-chlorophenylpiperazine. Clin Pharmacol Ther. 1988;43:605–608.
    1. Ferrari MD, Melamed E, Gawel MJ. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316–318.
    1. Kagaya A, Mikuni M, Kusumi I, Yamamoto Y, Takahashi K. Serotonin-induced acute desensitization of serotonin 2 receptors in human platelets via a mechanism involving protein kinase C. J Pharmacol Exp Ther. 1990;255:305–311.
    1. Sommerville B W. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurol. 1975;25:239–244.
    1. Johannes C B, Linet M S, Stewart W F, Celentano D D, Lipton R B, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurol. 1995;45:1076–1082.
    1. Sanoja R, Cervero F. Estrogen-dependent abdominal hyperalgesia induced by ovariectomy in adult mice: a model of functional abdominal pain. Pain. 2005;118:243–253.
    1. Neri I, Granella F, Nappi R, Manzoni G C et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993;17:31–37.
    1. J Mogil. Migraine Trust International Research Symposium; London UK: 2006. Personal communication.
    1. Ebner S, Dunbar M, McKinnon R D. Distinct Roles for PI3K in proliferation and survival of oligodedrocyte progenitor cells. J Neurosci Res. 2000;62:336–345.
    1. Mendelsohn M E. Nongenomic, estrogen receptor-mediated activation of endothelial nitric oxide synthase. How does it work? What does it mean? Circulation Res. 2000;87:956–960.
    1. Couse J F, Lindzey J, Grandien K et al. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERα) and estrogen receptor-beta (ERβ) messenger ribonucleic acid in the wild-type and ERα –knockout mouse. Endocrin. 1997;138:4613–4621.
    1. Puri V, Cui L, Liverman C S et al. Ovarian steroids regulate neuropeptides in the trigeminal ganglion. Neuropeptides. 2005;39(4):409–417.
    1. Puri V, Puri S, Svojanovsky S R, Mathur S et al. Effects of oestrogen on trigeminal ganglia in culture: implications for hormonal effects on migraine. Cephalalgia. 2005;36:33–42.
    1. McEwen B. Estrogen effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol. 2001;91:2785–2801.
    1. Pau C Y, Pau K Y, Spies H G. Putative estrogen receptor beta and alpha mRNA expression in male and female rhesus macaques. Mol Cell Endocrinol. 1998;146:59–68.
    1. Bjornstrom L, Sjoberg M. Estrogen receptor-dependent activation of AP-1 via non-genomic signaling. Nucl Recept. 2004;2
    1. Gangula P R, Zhao H, Wimalawansa S J, Supowit S C, DiPette D J, Yallampalli C. Pregnancy and steroid hormones enhance the systemic and regional hemodynamic effects of calcitonin gene-related peptide in rats. Biol Reprod. 2001;64:1776–1783.
    1. Durham P L, Sharma R V, Russo A F. Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci. 1997;17(24):9545–9553.
    1. Ginty D D. Calcium regulation of gene expression: isn’t that spatial? Neuron. 1997;18:183–186.
    1. Mulkey R M, Endo S, Shenolikar S, Malenka R C. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal longterm depression. Nature. 1994;369:486–488.
    1. Sun P, Enslen H, Myung P S, Maurer R A. Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev. 1994;8:2527–2539.
    1. Durham P L. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(Suppl 1)
    1. Jackson J L, Shimeall W, Sessums L Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. . 2010. Online First.
    1. Sutherland A, Sweet B V. Butterbur: an alternative therapy for migraine prevention. Am J Health Syst Pharm. 2010;67(9):705–711.
    1. Guzman F. Serotonin (5-HT): receptors, agonists and antagonists. . 2009.
    1. Schmuck K, Ullmer C, Kalkman H O, Probst A, Lubbert H. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci. 1996;8(5):959–967.
    1. Rang H P. Pharmacol, Edinburgh: Churchill Livingstone. 2003
    1. Saxena P R, Lawang A. a comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn Ther. 1985;277(2):235–252.
    1. Colpaert F C, Niemegeers C J, Janssen P A. In vivo evidence of partial agonist activity exerted by purpoted 5-hydroxytryptamine antagonists. Eur J Pharmacol. 1979;58(4):505–509.
    1. Ferrari M D, Roon K I, Lipton R B et al. Oral triptans (5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere